Myriad Genetics presents data on Vectra test
Myriad Genetics announced that its Myriad Autoimmune business unit will present new data on the Vectra test at the 2019 ACR/ARP Annual Meeting being held November 8-13 in Atlanta, Georgia. The key findings are that the Vectra test predicts the risk of radiographic progression within one year, and the Vectra score, in combination with other clinical measures, predicts the risk of a cardiovascular event in people with rheumatoid arthritis, or RA. "A hallmark feature of rheumatoid arthritis is inflammation, which increases the risk of joint damage, cardiovascular disease and other comorbidities," said Elena Hitraya, M.D., Chief Medical Officer at Myriad Autoimmune. "The data being presented by our academic collaborators at ACR show that the Vectra test accurately measures inflammation and can help predict patients' risk of adverse health outcomes, enabling clinicians to tailor precision treatment plans to achieve better outcomes."